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Abstract
HCV and HIV independently lead to immune dysregulation. The mechanisms leading to advanced liver disease progression in HCV/
HIV coinfected subjects remain unclear.
In this cross-sectional study, we assessed the association of HCV viremia, liver fibrosis, and immune response patterns in well-
characterized HIV phenotypes: Elite controllers (Elites), HIV controlled (ARTc), and HIV uncontrolled (ARTuc) matched by age and
race. Groups were stratified by HCV RNA status. Regulatory T-cell frequencies, T-cell activation (HLADR+CD38+), apoptosis
(Caspase-3+), and intracellular cytokines (interferon-g, IL-2, IL-17) were assessed using multiparametric flow-cytometry. Liver
fibrosis was scored by AST to platelet ratio index (APRI).
We found liver fibrosis (APRI) was 50% lower in Elites and ARTc compared to ARTuc. Higher liver fibrosis was associated with
significantly low CD4+ T cell counts (P<0.001, coefficient r=0.463). Immune activation varied by HIV phenotype but was not
modified by HCV viremia. HCV viremia was associated with elevated CD8 T-cell Caspase-3 in Elites, ARTuc, and HIV except ARTc.
CD8 T-cell Caspase-3 levels were significantly higher in HCV RNA+ Elites (P=0.04) and ARTuc (P=0.001) and HIV groups
(P=0.02) than ARTc. Importantly, ARTuc HCVRNA+ had significantly higher CD4 T-cell interleukin-17 levels than ARTuc HCVRNA
(P=0.005).
HIV control was associated with lower liver fibrosis in HCV/HIV co-infected women. HCV viremia is associated with an inflammatory
CD4 Th-17 phenotype in absence of HIV control and higher frequency of pro-apoptosis CD8 T-cells critical to avert progression of
HIV and HCV disease that is attenuated in ART controllers. Elite controllers with HCV viremia are more prone to CD8 T-cell apoptosis
than ART controllers, which could have negative consequences over time, highlighting the importance of ART control in HCV/HIV
coinfected individuals.
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acetate, Th-17 = T helper 17 cell, T-regs = regulatory T cells, WIHS = Women’s Interagency HIV Study.
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1. Introduction
Globally, 185 million individuals are estimated to be infected
with Hepatitis C virus (HCV)[1] and 3.4 to 4.4 million people in
the United States.[2] An estimated 25% of individuals infected
with human immunodeficiency virus (HIV) are co-infected with
HCV.[3] Life-threatening infections owing to AIDS have declined
with the advent of highly active antiretroviral therapy (HAART),
yet the incidence of morbidity and mortality from liver disease
has increased, and end-stage liver disease has become the leading
cause of non-AIDS-related death in HIV patients.[4] HCV/HIV
co-infected patients not receiving ART have more advanced liver
fibrosis.[5] Advanced fibrosis leads to poorer response to HCV
therapy[6] and increased rates of cirrhosis, liver failure, and
hepatocellular carcinoma.[7] The mechanisms leading to ad-
vanced liver disease progression in HCV/HIV co-infected subjects
remain unclear.
Chronic immune activation is a hallmark of HIV disease and is
associated with CD4 decline and HIV disease progression.[8,9]
Studies examining the effects of HCV co-infection on immune
activation are contradictory with some reporting an association
with CD8 T cell activation not confirmed in others.[10,11] HCV
progression in HIV infection has been reported to be owing to
HIV-mediated loss of CD4 helper T cells.[12] Liver damage in
chronic infection is predominantly from non-HCV-specific
inflammatory T cells infiltrating the liver.[13,14] To better
understand the immune mechanisms in HCV/HIV co-infected,
we examined the association of HCV viremia, hepatic fibrosis,
and immune response patterns namely CD4 numbers, T
regulatory cell frequency, immune activation, apoptosis, and T
cell function in well characterized HIV phenotypes: Elite
controllers, ART-controlled, ART-uncontrolled, and HIV neg-
atives. Liver disease progression was assessed by the AST to
platelet ratio index (APRI). We hypothesized that HCV viremia
affects both hepatic fibrosis and T cell phenotype and function in
HIV and HCV co-infected subjects.
2. Materials and methods
2.1. Patient population
The cross-sectional study included HCV seropositive women
enrolled in the Women’s Interagency HIV Study (WIHS), an
ongoing NIH multisite prospective study that includes HIV-
infected and HIV-uninfected women followed longitudinally
semiannually with clinical, laboratory assessment and collection
of biological specimens.[15] Overall, 32% of HIV-seropositive
womenwere co-infected withHCV, acquired before enrolment in
WIHS. Women who received HCV therapy were excluded. All
women gave written, informed consent for participation in
WIHS. TheWIHS studywas approved by all Institutional Review
Boards of participating institutions. HCV seropositivity was
documented by antibody to HCV by second-generation or third-
generation EIA (Ortho-Diagnostic Systems) and viremia by RT-
PCR (COBAS Amplicor HCV Detection Kit, Roche Diagnostic
Systems). HIV-RNA was measured using the isothermal nucleic
acid sequence-based amplification (NASBA/Nuclisens) method
(bioMerieaux)with limit ofdetectionof<50HIVRNAcopies/mL.
The study population was comprised of homogenous, well-
characterized HIV phenotypes stratified by serum HCV RNA-
positive (HCV RNA+) or -negative (HCV RNA <50IU/mL).
The HCV RNA-negative women did not have chronic HCV as
they had spontaneously cleared HCV infection and were
compared with those who had chronic HCV infection (detectable
HCV RNA in serum). Women were matched by age, race/
ethnicity, HCV RNA status within the following groups: Elite
controllers (Elites, n=19), defined as ART-naïve, CD4 >500
cells/mm3, VL <50 HIV RNA copies/mL, for at least 18 months;
HIV-controlled on antiretroviral therapy (ART) ([ARTc, n=20],
individuals who are currently on ART CD4 >350cells/mm3, VL
<50 HIV RNA copies/mL, for at least 18 months); HIV-
uncontrolled on ART (ARTuc, n=21, individuals who are
currently on ART but with detectable HIV RNA for at least 18
months); and HIV-negative (HIV, n=18) women.
2.2. Assessment of liver fibrosis
Liver fibrosis was assessed by the AST to platelet ratio index
(APRI), a noninvasive serum marker that has been shown to
reflect hepatic fibrosis accurately among chronic hepatitis C
patients with HIV.[16,17] APRI can be easily obtained in the
clinical setting, as it is calculated using serum aspartate
aminotransferase (upper limit of normal used 40IU/L) and
platelet count (109cells/L) and was used for this analysis as
described elsewhere.[16]
2.3. Assessment of Immune Markers
Immune activation and pro-apoptosis marker Caspase-3 in CD4
& CD8 T cells was measured on single cell level using
multiparametric flow cytometry on cryopreserved peripheral
blood mononuclear cells (PBMCs). PBMCs were washed and
stained with LIVE/DEAD Fixable Aqua Dead Cell Stain to
differentiate viable cells and stained with fluorochrome conju-
gated antibodies against the following cell surface markers CD3,
CD4, CD8, CD38, and HLA-DR. Following permeabilization,
cells were stained intracellularly with fluorochrome conjugated
anti-Caspase-3. PBMCswere fixed and acquired on a LSR-II flow
cytometer (BD Biosciences), and analyzed using FlowJo (Tree
Star Inc, Ashland, OR). Immune activation was defined as co-
expression of HLADR+CD38+ and intracellular Caspase-3
expression was assessed as a measure of cells prone to apoptosis
in live CD3+CD4+ and CD3+CD8+ T cells. Regulatory T cells
(T-regs) were enumerated in thawed PBMCs by measuring
transcription factor Forkhead box Protein 3 (FoxP3) expression
intracellularly on CD25+CD4+CD3+T cells, stained using
antibodies as described above. Regulatory T cells were defined
as CD4+CD25+FoxP3+ T cells. For assessing T cell functionality,
thawed PBMCs were stimulated with PMA (100ng/mL) and
Ionomycin (1mg/mL) for 6hours; Brefeldin A was used to block
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cytokine egress. Stimulated PBMCs were stained for T cell
subtyping using fluorochrome conjugated antibodies against
CD3, CD4, and CD8. Cells were permeabilized and stained
intracellularly with fluorochrome conjugated anti interferon
[IFN]-g, interleukin [IL]-2, and IL-17. PBMCs were fixed,
acquired as above.
2.4. Statistical analyses
Demographic and clinical characteristics at the time of the patient
visit were evaluated with proportions for categorical variables
and medians (IQRs) for continuous variables within these HIV
phenotypic and HCV viremia subgroups. For easy of interpret-
ability, we report the median (IQR), although variables lacking a
normal distribution were transformed to achieve normality (log10
or square root) for use in more powerful parametric tests.
Measures of fibrosis and immune markers were compared across
HCV viremia subgroups using the t test and compared across
HIV phenotypic subgroups using one-way analysis of variance
with post-hoc tests by the Tukey–Kramer method. Associations
were assessed with Spearman correlation coefficients. P values
<0.05 were considered statistically significant. All analyses were
completed with SAS v9.3 (SAS Institute, Cary, NC).
3. Results
3.1. Patients demographics
A total of 78 HCV antibody-positive women were included in this
study of whom 41 had chronic HCV (HCV RNA+) and 37 had
spontaneously cleared HCV (HCV RNA). Study participants’
characteristics are described in Table 1: 19 Elite Controllers, 20
ART-controlled, 21 ART-uncontrolled, and 18 HIV-negatives;
and by the presence of HCV viremia. HCV viremia across the
RNA+ groups was comparable (median Log10 6.1 [5.6–6.4 IQR]).
The median age was 49 years and 56% were African American.
3.2. Hepatic fibrosis varies by HIV phenotype
The presence of HCV viremia (chronic HCV) was significantly
associated with an increase in liver fibrosis marker as expected
(APRI median HCV RNA+ 0.40 vs. HCV RNA 0.21, P<
0.001) (Fig. 1A).We examinedwhether liver fibrosis measured by
APRI differed in various HIV phenotypes. As shown in Fig. 1B,
liver fibrosis varied significantly by HCV viremia in HIV
phenotypes. HCV viremia was significantly associated with
higher Log10 APRI compared to HCV RNA in each of the HIV
phenotype groups: Elites (P=0.004), ARTc (P=0.02), and
Table 1
Selected Patient Characteristics and Demographics.
Group HCV RNA N
HIV RNA (log10) CD4 (cells/mm
3) HCV RNA (log10) Age at visit, y Race AA
∗
Median (IQR) Median (IQR) Median (IQR) Median (IQR) n/total %
Total population NA 78 1.9 (1.9–2.5) 715 (432–1071) 6.1 (5.6–6.4) 49 (43–53) 44/78 56.00
Elite Controllers Negative 9 1.9 (1.9–1.9) 1025 (627–1021) UD 49 (39–51) 4/9 44.00
Positive 10 1.9 (1.9–1.9) 822 (675–1094) 5.9 (5.6–6.1) 44 (43–51) 6/10 60.00
ART Controlled Negative 10 1.9 (1.9–1.9) 875 (734–1195) UD 52 (44–57) 6/10 60.00
Positive 10 1.9 (1.9–1.9) 706 (576–851) 6.4 (5.8–6.6) 51 (48–54) 7/10 70.00
ART Uncontrolled Negative 10 3.7 (2.7–4.5) 273 (198–376) UD 48 (43–55) 5/10 50.00
Positive 11 3.0 (2.3–3.8) 252 (146–419) 6.3 (6.1–6.5) 47 (44–54) 7/11 64.00
HIV Negatives Negative 8 UD 1125 (915–1284) UD 50 (49–54) 4/8 50.00
Positive 10 UD 864 (677–1176) 5.8 (5.2–6.4) 44 (41–48) 5/10 50.00
ART=antiretroviral therapy, HCV=hepatitis C virus, HIV=human immune deficiency virus, IQR= interquartile range, N/A=not applicable, UD=Undetectable (HIV RNA <50copies/mL, HCV <50 IU/mL).
∗
AA includes African-American and Hispanic African American.
Figure 1. Correlates of Liver fibrosis. (A) Liver fibrosis was associated with HCV viremia; fibrosis serum marker APRI was used to assess liver fibrosis in study
participants. Significantly higher fibrosis was observed in women with HCV viremia. Significance between groups as depicted using t test. (B) Hepatic fibrosis varies
by HIV Phenotype: APRI Scores in Elites, ARTc, and ARTuc in HCV RNA+ and HCV RNA groups. Boxes represent 25th, 75th percentiles of the distribution
(interquartile range [IQR]) and whiskers represent minimum and maximum values. Median value is shown as the solid line. Significance as depicted (C) Liver fibrosis
was associated with lowCD4 numbers: Higher liver fibrosis (Log10 APRI) correlated significantly with lower CD4 numbers. Spearman correlation coefficient between
CD4 numbers and Log10 APRI as depicted.
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ARTuc (P=0.02). Importantly, the median APRI scores in Elites
(0.31) and ARTc (0.37) with HCV RNA+ were 50% lower
compared to ARTuc HCV RNA+ (0.74). This clinically lower
fibrosis score was observed with HIV viral control, either in
natural Elite control or via ART.
We further investigated the immune correlates of liver fibrosis
in HCV/HIV coinfected subjects. In this study, we found low
CD4 numbers to be significantly associated with liver fibrosis
(Log10 APRI) (P<0.001, coefficient r=0.463) (Fig. 1C). We
sought to examine whether liver fibrosis was associated with
alterations in systemic levels of CD4 T regulatory cells. In this
study, although not statistically significant, we found a positive
correlation between liver fibrosis scores Log10 APRI and T-reg
frequencies (P=0.06, r=0.237).
3.3. Higher immune activation and Caspase-3 levels are
associated with lower CD4 numbers
We investigated whether association of liver fibrosis with low
CD4 T cell count found in this study was attributable to chronic
immune activation (via activation induced cell death) or to
apoptotic loss of T cells. Overall, in all subjects, we found the
latter: lower CD4 numbers were associated with higher CD4 and
CD8 T cell activation (P<0.001 and P<0.001, respectively,
Supplemental Fig. 1A and B, http://links.lww.com/MD/B202)
and CD4 and CD8 T cell Caspase-3 levels (P=0.06 and p=
0.005, respectively, Supplemental Fig. 1C and D, http://links.
lww.com/MD/B202).
3.4. Immune Activation varies with HIV phenotypes and is
not modified by HCV viremia
We examined whether immune activation levels varied with the
presence of HCV viremia in the different HIV phenotypes. We
found, CD4 T cell activation varied by HIV phenotype, but did
not differ significantly by HCV viremia. Significant differences in
CD4 T cell activation were observed in HIV phenotypes.
Differences in CD4 T cell activation levels are shown in
Figure 2A. ARTuc subjects had significantly higher CD4 T cell
activation levels compared to HIV in HCV RNA+ (P=0.02).
Furthermore, ARTuc subjects had significantly higher CD4 T cell
activation levels compared to all other HIV phenotypic groups
within HCV RNA subjects (ARTc, P=0.02; Elite, P=0.001;
and HIV, P=0.01). Similarly, CD8 T cell activation varied by
HIV phenotype and HCV viremia did not modify CD8 T cell
activation within any HIV group. Significant differences in CD8
T cell activation were observed in HIV phenotypes. Differences in
CD8 T cell activation levels are shown in Figure 2B. ARTuc
subjects had significantly higher % CD8 CD38+HLADR+
compared to ARTc, and HIV, in both HCV RNA+ (P=
0.008 and P=0.003, respectively) and HCV RNA groups (P=
0.046 and P=0.01, respectively). The lack of a detectable
association between HCV viremia and the activation of CD4 and
CD8 T cells potentially suggests HCV pathogenesis may involve
pathways distinct from immune activation.
3.5. HCV viremia is associated with elevated levels of CD8
T cell Caspase-3 which is significantly lower in ARTc;
Elites with HCV viremia are more prone to CD8 T cell
apoptosis than ARTc
To evaluate potential mechanisms of the interaction betweenHCV
and HIV disease progression, we investigated constitutive
intracellular Caspase-3, a pro-apoptotic marker in CD4 and
CD8Tcells. In this study,we foundCaspase-3 expression varied by
HIV phenotypes and by HCV viremia. Differences were observed
acrossHIV phenotypes with lowest CD4 T cell Caspase-3 in ARTc
HCVRNA+group.Differences inCD4T cell Caspase-3 are shown
in Figure 3A. ARTc HCV RNA+ group had significantly lower
CD4 Caspase-3 compared to ARTuc HCV RNA+ (P=0.02).
Similarly, differences were observed across HIV phenotypes with
lowestCD8T cell Caspase-3 inARTcHCVRNA+ compared to all
groups. Differences in CD8 T-cell Caspase-3 are shown in
Figure 3B. CD8 T-cell Caspase-3 was significantly higher in
HCV RNA+ Elites (P=0.04), ARTuc (P=0.001), and HIV (P=
0.02) compared to ARTc HCV RNA+. Importantly, Elites HCV
RNA+ subjects had significantly higher CD8 T cell Caspase-3
compared to ARTc HCV RNA+.
Figure 2. Immune activation varies with HIV phenotypes and is not modified with HCV viremia, T-cell activation levels in HIV phenotypes by HCV RNA status. (A)
CD4 T-cell activation (B) CD8 T-cell activation in Elites, ARTc, ARTuc, and HIV-negatives in HCV RNA+ and HCV RNA groups. Boxes represent 25th, 75th
percentiles of the distribution (interquartile range IQR]) and whiskers represent minimum and maximum values. Median value is shown as the solid line. Significance
as depicted, t test was used across HCV viremia subgroups and 1-way analysis of variance across HIV phenotypes.
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HCV viremia was associated with elevated CD8 T cell
Caspase-3 in Elites, ARTuc, and HIV− (P=0.049) as compared
to HCV RNA− in each group except ARTc. In ARTc, however,
HCV viremia was associated with significantly lower Caspase-3
expression (P=0.03) compared to HCVRNA−. Thus, HCV
viremia could result in CD8 T cell loss via apoptosis; this is lower
in HCV RNA+ ARTc. The more pronounced decrease in this
group could be attributed to better CD8 T-cell survival owing to
high IL-2 production.
3.6. ART augments CD8 IL-2 production in HCV viremic
subjects
We assessed intracellular production of IL-2 and IFN-g in CD8 T
cells. The highest production of CD8 IL-2 was observed in ARTc
RNA+ compared to ARTc HCV RNA group (P=0.06), a
group with the lowest CD8 T-cell caspase-3 levels. Elites, ARTuc,
and HIV did not differ significantly by HCV RNA status in
CD8 IL-2+, IFN-g+, and IFN-g+IL-2+-producing T cells.
The mechanism by which ART impacts cell survival is likely by
augmenting IL-2 production. We found an inverse correlation of
CD4 and CD8 T -ell caspase-3 with IL-2 production (P=0.05,
r=0.677) and (P=0.050, r=0.683), respectively (data not
shown), in the ARTc RNA+ group, suggesting that ART
indirectly attenuates effects of HCV viremia by improving
immune dysregulation in HCV/HIV co-infected women.
3.7. HCV viremia in absence of HIV control is associated
with a proinflammatory CD4 Th-17 phenotype
Patterns of cytokines in CD4 T cells in HIV phenotypes by HCV
RNA status are shown in Figure 4. Elites and ARTc did not differ
in their frequency of CD4 IFN-g+, IL-2+, IFN-g+IL-2+, and IL-17
+-producing cells by HCV RNA status. CD4 IFN-g+ (Th-1) cells
were significantly elevated in HIV-negative HCV viremia
compared to HIV-negative HCV RNA subjects (P=0.02).
HCV viremia was associated with significantly higher IL-17 in
ARTuc subjects compared to ARTuc HCV RNA (P=0.005).
HCV viremia is associated with an increase in proinflammatory
IL17 CD4 (Th-17) phenotype in absence of HIV control. Thus,
replication of both HIV and HCV viruses appears to skew to a
proinflammatory Th-17 phenotype.
4. Discussion
In this study, we addressed the hypothesis that coinfection with
HCV and HIV affects both hepatic fibrosis and T cell phenotype
and function. We report, in well characterized HIV phenotypes,
the effects of chronic HCV (presence of HCV viremia) on liver
fibrosis, CD4 T cell numbers, T regulatory cell frequency,
immune activation, apoptosis, and T cell cytokine production.
APRI was used for assessment of liver fibrosis. The prognostic
utility of APRI has been assessed in this cohort earlier and found
to be independently associated with all-cause and liver mortality
in HCV/HIV-co-infected women.[18] We found HCV viremia to
be significantly associated with worse liver fibrosis as expected.
Contrary to earlier reports,[19] recent reports suggest that rates of
advanced fibrosis and liver disease progression in persons with
controlled HIV are similar to the rates of those with HCV
alone.[20,21] The difference in liver fibrosis with HIV control was
compelling: 50% lower with HIV control by ART or in Elites as
compared to ARTuc.
Chronic HCV likely alters T-cell frequencies as well as
phenotype and function. HCV/HIV coinfection is known to be
associated with lower CD4 counts and a smaller CD4-cell
recovery[22,23] attributed to homeostatic alterations in CD4
subsets or thymic defects.[24–26] Our data show a significant
association of lower CD4 numbers with worse fibrosis suggesting
that immune failure is a strong correlate of liver fibrosis in HCV/
HIV coinfected patients.
HIV infection is associated with chronic immune activation[27]
and activation-induced cell death is one of the proposed
mechanisms of immune decline.[28] HIV control usually requires
long-term ART, but it is also seen in Elite controllers, who do not
require ART. However, some individuals do not achieve HIV
control despite ART (ARTuc). Our study is the first to study
Figure 3. CD8 T-cell Caspase-3 level varies with HCV viremia and is ameliorated in ARTc, Caspase-3 levels in HIV phenotypes by HCV RNA status. (A) CD4 T-cell
Caspase-3 levels and (B) CD8 T-cell Caspase-3 levels in Elites, ARTc, ARTuc, and HIV negatives in HCV RNA+ and HCVRNA groups. Boxes represent 25th, 75th
percentiles of the distribution (interquartile range [IQR]) and whiskers represent minimum andmaximum values. Median value is shown as the solid line. Significance
as depicted, t test was used across HCV viremia subgroups and 1-way analysis of variance across HIV phenotypes.
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immune function in women with chronic HCV and well
characterized different HIV status and control. Our data show
that immune activation in HCV/HIV infection varies by HIV
phenotype but does not differ significantly by HCV viremia.
Previous studies have shown CD8 T-cell activation to be
elevated in HCV/HIV coinfected subjects and persisted despite
antiretroviral control of HIV.[10,29] More recent studies have
reported CD8 T-cell activation is not enhanced in HCV/HIV
coinfected[11,24,30] and HCV/HIV coinfected subjects have
activated CD4 T cells.[11,24] An earlier study in the WIHS cohort
by Kovacs et al[29] reported elevated CD8 T-cell activation in
HCV/HIV coinfected subjects, wherein HIV-1 disease in most
women was at an early stage: almost 50% were untreated and
only 7.7% were receiving HAART. In contrast, a more recent
study in WIHS cohort by Kuniholm et al[24] assessing T-cell
phenotype in HIV-infected women stratified by HCV RNA did
not find CD8 T-cell activation in HCV/HIV coinfected women. A
Scandinavian study by Gonzalez et al[10] showed immune
activation as determined by CD38 expression in T cells to be
more pronounced despite successful suppression of HIV in HCV/
HIV coinfected subjects than in the appropriate monoinfected
controls. Participants in the Scandinavian study were on
combination of pegylated IFN-a (IFNa) and ribavirin, with
64% of patients reaching a sustained virological response to
treatment.[10] The differences in our results from the Scandina-
vian study could be because of differences in definition of immune
activation (CD38+HLADR+ vs. CD38+) and that our partic-
ipants were not on IFN-based HCV therapy. IFN-a is known to
contribute to CD8 T cell activation as was shown in a study in
untreated HIV-infected subjects receiving IFN therapy.[31] None
of these previous reports studied carefully selected different HIV
phenotypes but rather, chose unselected HIV-positive subjects.
Although there are fewer subjects in each group, HIV Elites are
uncommon and our groups were carefully chosen for HIV status
with matched HCV viremia within groups.
Apoptosis or programmed cell death can be induced by a
variety of stimuli includingHIV andHCV. A study byNunez et al
showed using Annexin V labeling that T-cell apoptosis was
significantly higher in HCV/HIV coinfected than in monoinfected
patients. Plasma HCV RNA levels were not associated with the
levels of apoptosis in CD4+ or in CD8+ T cells.[32] Another study
by Korner et al using the TUNEL assay to measure apoptosis
reported that HCV co-infection disproportionately increased
rates of apoptosis in CD4+ T-cells from untreated HIV-positive
patients that was correlated with HIV, but not HCV, viral
loads.[33] In our study using constitutive intracellular Caspase-3
as a measure of cells prone to apoptosis, we show CD8 T cell
Caspase-3 is elevated in all groups: Elites, ARTuc, and HIV
except ARTc. Elites are known to have higher CD8 T-cell
Caspase-3 compared to HIV.[34] In this study, importantly we
show that presence of HCV viremia can result in higher CD8 T
cell apoptosis in Elites than Elites HCV RNA and significantly
higher compared to ARTc with HCV viremia. Thus, Elites with
HCV viremia could have negative consequences over time. CD8
T-Cell Caspase-3 was lowest in ART controllers. The role of CD8
T cells in viral clearance is known and recent reports have shown
that clearance of chronic HCV infection can occur after exposing
HIV/HCV coinfected patients to HAART.[35–37] In our subjects,
ART appears to attenuate HCV-mediated immune dysregulation
likely by improving T-cell survival.
HIV infection is associated with an imbalance in T-helper cell
subsets.[38] The imbalance of T-helper lymphocytes is also known
to play an important role in immune pathogenesis of chronic
hepatitis C virus (HCV) infection.[39] Our data suggest presence
Figure 4. HCV viremia is associated with a proinflammatory CD4 Th-17 phenotype in absence of HIV control, CD4 T-cell intracellular cytokine production in HIV
phenotypes by HCV RNA status: IL-17, IFN-g, IL-2, and IFN-g and IL-2 production in (A) Elites (upper left), (B) ARTc (upper right), (C) ARTuc (lower left), and (d) HIV-
negative (lower right). The Bar graphs compare percentage of each value of HCV RNA+ and RNA to the total and are displayed as 100% stacked columns.
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of HCV viremia alone is associated with frequency of Th-1 (IFN-
g) cells, as observed in HIV-negative subjects with HCV viremia.
Importantly, we report significantly higher frequency of IL-17+
cells in subjects with HIV and HCV replication, representing an
inflammatory CD4 Th-17 cell phenotype. Hepatitis C virus
promotes T-helper (Th) 17 responses through thymic stromal
lymphopoietin production by infected hepatocytes.[40] IL-17-
producing CD4+ Th-17 cells have been reported to trigger tissue
inflammation and are important contributors to hepatic
inflammation and liver cirrhosis[41] and may be important
contributors to hepatic inflammation and liver fibrosis and
cirrhosis in HCV/HIV co-infected subjects. Our data show in
absence of HIV control that HCV viremia is associated with CD4
Th-17 phenotype, highlighting the importance of HIV control in
HCV/HIV coinfected individuals.
The data presented in this study should be interpreted in light
of limitations of the study. HCV and HIV pathogenesis studies
are predominantly conducted in men and this study was
conducted in women only. Although this may seem a limitation,
the WIHS cohort, of HIV- and HCV- infected and uninfected
women, allowed us to study effects of HCV viremia in unique
well characterized HIV phenotypes including the least prevalent
(<1%) elite controllers that were matched for age and race. We
used noninvasive markers of fibrosis APRI, which can be utilized
retrospectively. As this was a retrospective analysis, liver biopsy
and Fibroscan, while more sensitive for fibrosis, were not
available in these subjects. Age has been used as a proxy for
length of infection[42], which may affect the results, but our HIV
groups were matched by age. The subjects may migrate from one
HIV phenotype to another over time, but these women were
carefully elected in this cross-sectional study to be sustained in the
HIV phenotype for a period of at least 18 months. Although our
sample size was small, this study is unique in the careful study
design of extremely well characterized HIV and HCV pheno-
types. Importantly, the study participants were comprised of
homogenous, well characterized HIV phenotypes stratified by
HCV RNA-negative and –positive groups, not on HCV therapy.
Prospective investigations are needed to establish the contribu-
tion of these findings including the role of IL-17 in liver disease
progression.
5. Conclusions
Hepatic fibrosis varied byHCV viremia andHIV phenotype. HIV
control Elite or via ART was associated with lower liver fibrosis
in HCV/HIV coinfected women. Chronic HCV inHIV coinfected
individuals affects T-cell phenotype and function. Immune
activation varied within distinct HIV phenotypes, but did not
differ significantly with HCV viremia. HCV viremia was
associated with elevated levels of CD8 T-cell Caspase-3 in Elites,
ART–uncontrolled, and HIV-negative except in ART-controlled
women. Importantly, we report that HCV viremia is associated
with an inflammatory CD4 Th-17 phenotype in absence of HIV
control, which has implications to hepatic injury and higher
frequency of pro-apoptosis CD8 T cells critical to avert
progression of HIV and HCV diseases. Elite controllers with
HCV viremia are more prone to CD8 T-cell apoptosis than ART
controllers, which could have negative consequences over time.
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